SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gerald Walls who wrote (622)12/10/1998 4:13:00 AM
From: LORD ERNIE  Read Replies (1) of 857
 
Three things I found.
1° The apply for approval in Europe must be answered within 210 days.
2° The spin-off they will make is to create a new firm, with only the Hepatitis-know-how. The new shares will go to the shareholders of HEMI. The old firm will continue to work on MS.
3° There is a big possibility that HEMI will trade on EASDAQ.
:-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News